Gilead Looks to Machine Learning with insitro NASH Collaboration
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)
Published: 25 Apr-2019
DOI: 10.3833/pdr.v2019.i4.2419 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Undeterred by the failure of its lead non-alcoholic steatohepatitis (NASH) drug, selonsertib, in a key Phase III trial as announced in February 2019, Gilead has agreed to a three-year collaboration with insitro to develop NASH therapies for up to five targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS